Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.50 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | OXTR | P30559 | 1/20 | 0.43 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.43 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29336125 | 0.89 | RORC (0.50) | PTGESTAS2R14CNR1CNR2HTT | |
| SCHEMBL29334346 | 0.86 | PTGES (0.47) | PTGESTAS2R14HTT | |
| SCHEMBL20871141 | 0.85 | PTGES (0.46) | PTGESTAS2R14 | |
| SCHEMBL22340495 | 0.85 | PTGES (0.47) | PTGESTAS2R14CNR1CNR2HTT | |
| SCHEMBL22340857 | 0.85 | PTGES (0.50) | PTGESTAS2R14HTTEPHX2 | |
| SCHEMBL31305923 | 0.84 | APLNR (0.46) | PTGESTAS2R14MEN1KMT2AHTT | |
| SCHEMBL20870834 | 0.84 | PTGES (0.45) | PTGESTAS2R14CNR2 | |
| SCHEMBL22340458 | 0.84 | PTGES (0.45) | PTGESTAS2R14CNR2 | |
| SCHEMBL20870805 | 0.84 | PTGES (0.45) | PTGESTAS2R14CNR2 | |
| SCHEMBL29335919 | 0.84 | PTGES (0.45) | PTGESTAS2R14CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3707132-B1 | NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES | UNIV PARIS SACLAY (FR) | 2024-07-17 | — | — | EP | disclosed |
| US-11034646-B2 | Method for the synthesis of unsymmetrical tertiary amines | Universite Paris-Saclay (FR) | 2021-06-15 | — | — | US | disclosed |
| US-20200255369-A1 | NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES | Universite Paris-Saclay (FR) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255369-A1 | NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES | ADH1C, ADH1A, ADH5 | PTGES 2690/4885TAS2R14 1287/4885MEN1 134/4885 |
| US-11034646-B2 | Method for the synthesis of unsymmetrical tertiary amines | ADH1C, PNMT, ADH1A | PTGES 2575/4885TAS2R14 1535/4885MEN1 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.